← Back to Clinical Trials
Recruiting NCT06496711

NCT06496711 IMPLEMENT - Model Project for Quality-assured Exercise Therapy for Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06496711
Status Recruiting
Phase
Sponsor University of Cologne
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 600 participants
Start Date 2023-09-01
Primary Completion 2025-11-30

Eligibility & Interventions

Sex All sexes
Min Age 5 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cancer Patients; Institutions and their employees in the treatment and/or counseling of cancer patients

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 600 participants in total. It began in 2023-09-01 with a primary completion date of 2025-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

IMPLEMENT aims to develop, test and establish a sustainable access structure for quality-assured oncological exercise therapy (qOET) in Germany as a model within the funding period of three years. This will be done in three phases: Phase 1: In the first step, a characterization of the existing implementation structures and the existing barriers and needs as well as the establishment of the cooperation with the most important actors in the care system will take place. Phase 2: In the subsequent implementation process, concrete measures are practically implemented in subprojects for specific target groups (children/adolescents, adults) and specific regions (rural, urban) as well as the digital solutions and interface management. With the help of a mixed-methods design, the barriers and facilitating factors of the implementation of area-wide qSBT will be investigated during the project and fed into a "learning system" for adaptation and improvement. Phase 3: The success of the measures to increase patient participation in qOET and the development of the structures as well as the barrier and facilitating factors for an effective implementation will be addressed in a before-after comparison through evaluation steps and an economic accompanying evaluation will be carried out.

Eligibility Criteria

Inclusion Criteria: * Patients with cancer * Healthcare providers (e.g. Medical Doctors, physiotherapists, nurses, psychologists) involved in the treatment and/or counseling of cancer patients, including aftercare. Exclusion Criteria (Cancer Patients): * Psychological and/or physical limitations that do not allow participation in quality-assured sports and exercise therapy (e.g. unstable cardiac arrhythmias)

Contact & Investigator

Central Contact

Freerk Baumann, Prof. Dr.

✉ freerk.baumann@uk-koeln.de

📞 0049 0221 478 42646

Principal Investigator

Freerk Baumann, Prof. Dr.

PRINCIPAL INVESTIGATOR

University of Cologne

Frequently Asked Questions

Who can join the NCT06496711 clinical trial?

This trial is open to participants of all sexes, aged 5 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06496711 currently recruiting?

Yes, NCT06496711 is actively recruiting participants. Contact the research team at freerk.baumann@uk-koeln.de for enrollment information.

Where is the NCT06496711 trial being conducted?

This trial is being conducted at Cologne, Germany.

Who is sponsoring the NCT06496711 clinical trial?

NCT06496711 is sponsored by University of Cologne. The principal investigator is Freerk Baumann, Prof. Dr. at University of Cologne. The trial plans to enroll 600 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology